Motomura S, Kanamori H, Maruta A, Kodama F, Ohkubo T
First Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
Am J Hematol. 1991 Sep;38(1):67-8. doi: 10.1002/ajh.2830380112.
Leukemic transformation (LT) free survival was studied in 30 patients with myelodysplastic syndromes (MDS). In 15 cases, 4-6 micrograms/day of 1-hydroxyvitamin D3 was administered, for a median duration of 17 months (D-group), other subjects had no therapy (N group). LT free survival of the D group had significant advantage over that of the N group according to the Kaplan-Meier method (P less than 0.001). In addition, 7 cases in the N group developed acute leukemia, in contrast to only one in the D group (P less than 0.05). These results suggest that oral administration of 1-hydroxyvitamin D3 prevents the progression of MDS to overt leukemia under the effect of differentiation capacity from blasts to monocytes.
对30例骨髓增生异常综合征（MDS）患者进行了无白血病转化（LT）生存期的研究。15例患者每天服用4 - 6微克的1 - 羟基维生素D3，中位疗程为17个月（D组），其他患者未接受治疗（N组）。根据Kaplan - Meier法，D组的无LT生存期显著优于N组（P < 0.001）。此外，N组有7例发生急性白血病，而D组仅有1例（P < 0.05）。这些结果表明，口服1 - 羟基维生素D3在从原始细胞向单核细胞的分化能力作用下，可预防MDS进展为明显的白血病。
